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ABSTRACT
Introduction: Treatment options for type 2 diabetes
are becoming increasingly complex with people often
prescribed multiple medications, and may include both
oral and injectable therapies. There is ongoing debate
about which drug classes provide the optimum
second-line and third-line treatment options. In the real
world, patient adherence and persistence determines
medication effectiveness. A better understanding of
adherence may help inform the choice of second-line
and third-line drug classes.
Methods and analysis: This systematic review will
compare adherence and persistence rates across the
different classes of medication available to people with
type 2 diabetes. It will include all identified studies
comparing medication adherence or persistence
between two or more glucose-lowering medications in
people with type 2 diabetes. Research databases
(MEDLINE, EMBASE, The Cochrane Library, The
Register of Controlled Trials, PsychINFO and CINAHL)
will be searched for relevant articles, using a
comprehensive search strategy. All identified
medication trials and observational studies will be
included which compare adherence or persistence
across classes of diabetes medication. The
characteristics and outcomes of all the included studies
will be reported along with a study quality grade,
assessed using the Cochrane Risk Assessment Tool.
The quality of adjustment for confounders of
adherence or persistence will be reported for each
study. Where multiple (n ≥3) studies provide compare
adherence or persistence across the same 2 medication
classes, a meta-analysis will be performed.
Ethics and dissemination: No ethics approval is
required. This review and meta-analysis (where
possible) will provide important information on the
relative patient adherence and persistence, with the
different classes of diabetes therapies. Once complete,
the results will be made available by peer-reviewed
publication.
Trial registration number: CRD42015027865.
INTRODUCTION
Type 2 diabetes is a growing problem world-
wide.1 Alongside this increased prevalence
comes an increased burden of disease from
complications, which are potentially prevent-
able.2 The importance of patient education
and promoting self-care has long been recog-
nised as a key component in chronic disease
management and improving patient out-
comes.3 One component of self-care is
adherence to often complicated medication
regimes. Good adherence is associated with
reduced risk of diabetes complications,
reduced mortality and reduced economic
burden.4–6 However, a substantial proportion
of people with type 2 diabetes do not take
medication as prescribed, with only 67–85%
of oral medication doses taken, and approxi-
mately 60% of insulin doses.7
In recent years, new medication classes
have been introduced which have increased
the complexity of diabetes treatment algo-
rithms leading to multiple second-line and
third-line options.8–10 Selection from these
options usually follows a discussion with the
patient and involves assessing potential efﬁ-
cacy, contraindications, potential side effects
(especially hypoglycaemia risk and weight
change), medication cost, frequency of
dosing, whether the medication is required
to be administered as an injection and
whether monitoring of blood indices is
required. However, a key component of
medication effectiveness, rarely discussed at
the outset, is patient adherence, and this is
especially important in diabetes as overall
adherence to therapies is poor.
Adherence is determined by many factors:
patient-related, condition-related, socio-
economic, health system-related and
therapy-related (table 1) factors.11 While
interventions aimed at improving medication
adherence should target all these main
domains, it is the therapy-related component
that will predominantly inﬂuence which
therapy is chosen. Identiﬁcation of any sub-
stantial differences in adherence rates
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between medication classes is vitally important. While
there have been previous reviews of medication adher-
ence in type 2 diabetes, these have not speciﬁcally inter-
rogated differences in adherence rates between
medications.7 12–16 The side-effect proﬁle of each class
of diabetes medication is different, and is likely to have
a differential impact on adherence. Similarly, different
dosing regimens and administration routes between
classes will inﬂuence adherence. Knowledge of any dif-
ferential in adherence rates between classes will help to
inform prescribing practice, and is currently lacking.
A wide range of terms have been used to describe
patient use (or non-use) of prescribed medications
including: adherence, compliance, concordance and
persistence. Two distinct patterns of medication use are
described by these terms; missed medication doses (gen-
erally described by the terms adherence, compliance
and concordance) and duration of use before termin-
ation (persistence). The term concordance is preferred
by some to emphasise the joint agreement by the pre-
scribing physician and the patient to use the prescribed
medication in a certain way.17 ‘Adherence’ is the term
recommended for use by WHO,18 however, the term
most commonly used in the literature is compliance.19
For this study, we will use the term adherence.
Persistence with medication is the preferred term to
refer to the duration of medication use.19 This is
another key component of effectiveness of clinical medi-
cation, and is closely linked with medication adherence.
Knowing the relative adherence and persistence rates
of medications used for the treatment of type 2 diabetes
is important when selecting from the increasingly
complex array of therapies.
METHODS
Research objective
This systematic review will compare adherence and per-
sistence rates between different classes of therapies for
the treatment of hyperglycaemia in people with type 2
diabetes. It will attempt to answer the question: Are
there substantially different adherence and persistence
rates between the different classes of therapies available
for type 2 diabetes? The key components of the study
are outlined in table 2.
Literature that compares adherence rates and persist-
ence between different medication classes will be identi-
ﬁed and, where appropriate, synthesised and summarised.
This review forms an early component of a wider research
theme: the University of Surrey-Lilly Real World Evidence
projects. These projects aim to use routine primary care
records to identify areas for improvement of diabetes man-
agement. This review will inform further research as part
of these projects, and by the wider research community
into medication adherence.
Interventions
The adherence and persistence with all available
glucose-lowering therapies will be explored. These will
be grouped by drug class for comparison (table 3). We
will include medications which are in current use, those
which have been previously withdrawn or discontinued,
and those which have not yet been licensed, if sufﬁcient
data on adherence is available. Data on medications
which are not currently in general use may provide
important information on the adherence to the medica-
tion class, for example, insulin inhalation (trade name,
Exubera)—an inhaled insulin discontinued in 2007—
may provide useful information on adherence to
inhaled insulin use.
We will perform secondary analyses to identify differ-
ences in adherence and persistence within classes where
daily, weekly and depot preparations exist (such as
glucagone-like peptide 1 agonists). We will also perform
a secondary analysis of the difference in adherence and
persistence with the biguanide metformin standard
Table 2 The key components of the systematic review
described using the standard PICOS (Participants,
Interventions, Comparisons, Outcomes and Study design)
formula
Participants People with type 2 diabetes who required
treatment with one or more medications
Interventions Glucose-lowering medications
Comparisons Other classes of glucose-lowering
medications (metformin to be used as the
default comparator where available)
Outcomes Any reported measure of patient adherence
or persistence with treatment
Study design Both interventional and observational
studies
Table 1 Factors previously identified as associated with
medication adherence in people with diabetes categorised
by the five dimensions affecting adherence as defined by
WHO11
Dimension
Factors associated with reduced
adherence
Patient-related Younger age,5 26–28 female
gender,5 26 27 smoking,5 impulsivity,29
ethnic minority groups27 30 31
Socioeconomic Lower socioeconomic status,28 32 lack
of financial resources/increased
medication costs,26 33 34 lower
education level,27 35 lack of family
support36
Condition-related Presence of depression,37 or other
chronic diseases,38–40 shorter duration
of diabetes,24 fewer diabetes
complications28
Health system Healthcare centre/clinic,41 increased
distance to nearest pharmacy,42 lower
continuity of care43
Therapy-related Concurrent medication use,25 38 44 45
adverse effects,46 47 poor previous
experience with medication42
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formulation and metformin-modiﬁed release. In our
experience, there is a substantial difference in tolerabil-
ity of these preparations.
Comparisons
Medication classes will be compared (within individual
studies) with other available medication classes. Given
the previously identiﬁed7 heterogeneity in studies
designs, and both measures and reporting methods of
adherence, it is likely that direct comparison of classes
will have to be intrastudy only. For this reason, studies
reporting adherence or persistence rates in a single
drug class will be excluded.
Outcome measures
Adherence and persistence will be deﬁned as:
▸ Adherence: The proportion (or estimated proportion)
of doses taken over a deﬁned time, or the proportion
of people attaining a deﬁned level of adherence.
Where possible, we will use the recommended deﬁn-
ition of adequate adherence to be a medication pos-
session ratio (MPR) ≥80% or proportion of days
covered (PDC) ≥80%20 or proportion of doses taken
(when measured directly) to be ≥80%. MPR is
deﬁned as the number of days’ supply of medication
divided by the medication reﬁll interval (with some
variation in the formula used). PDC is deﬁned as pro-
portion of days the patient has medication available
in a deﬁned period. PDC allows adjustment for over-
laps caused by early collection of prescriptions.
▸ Persistence: The proportion of people who remain on
a therapy after a deﬁned period of time, or the mean
duration of therapy. Persistence may be deﬁned as
medication reﬁlls consistent with ongoing use of the
medication.20 Failure to reﬁll a prescription after a
predeﬁned gap indicates non-persistence.
Differing deﬁnitions of adherence affect outcomes,
with the impact of this effect apparent when stratifying
studies by the deﬁnition used.21 We will duplicate this
method; stratifying studies by the threshold used to
deﬁne adequate adherence, and use a similar method to
stratify studies by the deﬁnition of persistence (see Data
synthesis section).
Primary outcomes
▸ Comparison of adherence or persistence between
metformin (standard formulation) and other hypo-
glycaemic agents.
Secondary outcomes
▸ Comparison of adherence or persistence between two
or more hypoglycaemic agents, where metformin is
not the comparator.
▸ Any differences between interventional and observa-
tional reports of studies.
▸ Analysis of the impact of the deﬁnition of adher-
ence/persistence on the relative adherence rates to
diabetes therapies.
▸ Any reported reasons for differences in adherence or
persistence between medication classes.
▸ Any reported differences in disease outcomes (gly-
caemic control or diabetes complications) in patients
due to differing adherence rates between medication
classes.
▸ Assessment of the quality of adjustment for confound-
ing in existing studies.
Included study types
All interventional and observational studies comparing
adherence rates and/or persistence with two or more
diabetes medication classes will be included.
Interventional studies types will include randomised,
non-randomised, and cross-over trials. Interventions can
include interventions aimed at improving adherence or
the use of medication as the intervention (clinical
trials). Observational studies will include cohort and
cross-sectional studies (eg, those with surveys of patient
reported compliance).
Study inclusion criteria
Studies will be included in the review if all the participants
taking the medications of interest have type 2 diabetes.
Studies from the community setting will be included; hos-
pital outpatient studies and community studies, including
primary care. Studies measuring adherence using the fol-
lowing methods will be included; self-reported measures,
clinician estimated adherence, calculated adherence rates
from prescribing or dispensing data, or electronic moni-
toring of medication use. Electronic monitoring technol-
ogy broadly involves the use of a medication container
which collects data on bottle opening.
Studies will be included if they report a sufﬁcient
measure of adherence and/or persistence. For this
purpose, adherence will be deﬁned as the proportion of
Table 3 Classes of medications used in type 2 diabetes
Oral agents Injectable agents
Biguanides Short and rapid-acting human
and animal insulins
Thiazolidinediones
(‘glitazones’)
Short and rapid-acting insulin
analogues
Dual PPAR agonists Medium and long-acting
human and animal insulins
Sulfonylureas Medium and long-acting insulin
analogues
Meglitinides (‘glinides’) Mixed insulins
DPP-4 inhibitors
(‘gliptins’)
GLP-1 agonists
Alpha-glucosidase
inhibitors
Combined GLP-1 agonists and
insulin
Amylin analogues Inhaled agents
SGLT 2 inhibitors
(‘gliflozins’)
Inhaled insulins
Combination oral
preparations
DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1;
PPAR, peroxisome proliferator-activated receptor; SGLT-2,
sodium-glucose co-transporter 2.
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doses taken over a given time period (period deﬁned in
the study); reported as a fraction; or reported as a pro-
portion of patients achieving a predeﬁned level of
adherence. Persistence will be deﬁned as the proportion
of people who remain taking a therapy after a speciﬁed
treatment period or the mean number of days until dis-
continuation. These deﬁnitions are consistent with previ-
ous work.7
Exclusion criteria
Studies will be excluded if
▸ They include populations with only type 1 diabetes,
people without diabetes taking the medication of
interest, or mixed populations where adherence rates
in those with type 2 diabetes were not reported
separately.
▸ The medications studied are not used to treat
diabetes.
▸ No clear measure of adherence or persistence is
reported.
▸ Adherence or persistence rates in diabetes during
pregnancy.
▸ Adherence or persistence rates with medications
from a single class only are reported.
▸ Adherence or persistence rates are not reported sep-
arately by individual drug or by drug class.
▸ The study participants are hospital inpatients or inpa-
tients at another institution.
▸ The study participants have medication administered
by a caregiver or professional.
Search method
Studies will be obtained by searching the following
databases:
▸ MEDLINE
▸ EMBASE
▸ The Cochrane Library including the Cochrane
Controlled Trials Register (CENTRAL) and the
Database of reviews of effectiveness (DARE) and the
NHS Health Economics Database
▸ The meta Register of Controlled Trials (http://www.
controlled-trials.com)
▸ PsychINFO
▸ CINAHL
Additionally, bibliographic searches of the included
studies will also be performed. Only studies published
from 2006 onwards will be included to provide a
summary of the most recent 10 years of publications.
Search terms
The search strategy detailed in online supplementary
appendix 1 will be used to search the MEDLINE database.
This strategy will be adapted to apply to the other included
databases. Only English language studies will be included.
Study selection
Two clinicians will independently review the titles and
abstracts of all the articles identiﬁed using the search
terms described. Studies will be included which match
the above inclusion criteria and do not have any exclu-
sion characteristics. Studies will be eliminated if both
reviewers agreed that the study did not meet the
required criteria. Studies which either or both reviewers
feel merit further analysis will be included for full paper
review. Full articles will be collected and collated into
unique studies. Full papers for each study will be
reviewed separately by each reviewer against the inclu-
sion and exclusion criteria. In the case of disagreement
between the reviewers, a third reviewer will be included
to resolve the discrepancy. If amendments are needed to
the inclusion or exclusion criteria to clarify whether a
particular study is included or excluded these will be
reported in the ﬁnal review manuscript alongside details
of the paper(s) in question.
Data extraction
Data will be extracted using a standardised method into a
preformatted database. Data will be extracted on study type
and intervention (if relevant), study location, sample size,
study population characteristics (age, gender, comorbid-
ities, concurrent medication use—including pill burden,
and duration of diabetes), duration of follow-up, inclusion
and exclusion criteria, and funding sources. Outcome data
extracted will comprise adherence or persistence measure-
ment method, adherence values, persistence values, sug-
gested or measured reasons for any reported interclass
adherence or persistence differences, and impact on
glucose control and diabetes complications. All extracted
data will be veriﬁed by a second reviewer.
Assessment of evidence quality
The internal validity of all included studies will be assessed
using the Cochrane risk assessment tools. This enables
evaluation of clinical trials based on the following criteria;
sequence generation, allocation concealment, blinding of
participants, personnel and outcome assessors, incomplete
outcome data, selective outcome reporting, and other
sources of bias. All publications will be categorised as
either low risk, unclear risk or high risk or bias. For cohort
studies, the risk assessment tool enables assessment based
on the following domains; selection of population, assess-
ment of exposure, assessment of the present of outcomes
at baseline (not relevant here), matching or adjustment
for confounders, identiﬁcation of prognostic variables,
assessment of the outcome measure, adequacy of
follow-up, and similarity of co-interventions between
groups. We will report the quality of all the included
studies, and will comment on the overall impact of data
quality on the conclusions drawn by the review. We will
rank the overall quality of evidence on this topic using the
GRADE (Grading of Recommendations Assessment,
Development and Evaluation) scoring system.22
Data analysis and presentation
We will provide a description of the number of studies
included and excluded at each stage of the search
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process. A study ﬂow diagram will be incorporated in
the standard form suggested by the Preferred Reporting
Items for Systematic reviews and Meta-Analyses
(PRISMA) statement.23 The characteristics of all the
studies included will be presented with the study
outcome ﬁndings. We will provide a text summary of the
main results, and a discussion including details of the
quality of existing evidence and recommendations for
future research.
Data synthesis
Factors such as age, gender, comorbidities and concur-
rent medication use inﬂuence both medication choice
and adherence.5 24 25 Untangling the contribution to
non-adherence caused by these confounders from that
caused by the medication class will be complex. We will
address this issue in several ways:
1. We will perform a comparison of adherence between
classes in randomised trials. Where randomisation is
sufﬁcient, any differences in adherence are likely to
be related to medication factors only.
2. In observational studies, we will assess and report the
methods used to identify and adjust for potential
confounding factors (table 1). We will report which
confounders have been adjusted for in each included
study, and report those which have not been mea-
sured or reported. We will comment on the limitation
of the methods used to control for confounders
where this has been performed.
3. We compare relative adherence rates for each drug
comparison in all studies (via meta-analysis as
described below) with those with a method of adjust-
ment or controlling for confounders. These methods
may include adjustment via statistical methods, such
as regression analysis, or by controlling for confound-
ing via case selection (such as case–control studies).
4. We will perform meta-analyses for each pair of medi-
cation classes compared where there are a sufﬁcient
number of studies enabling comparison (n ≥3). The
possible pairwise comparisons are shown in ﬁgure 1.
For each pairwise comparison, we will undertake the
following analyses: a comparison of the proportion of
people adherent to medication all studies (stratiﬁed
by the deﬁnition used for adherence; all deﬁnitions,
≥75% of doses taken/MPR/PDC, ≥80% doses
taken/MPR/PDC, ≥90% doses taken/MPR/PDC).
5. A comparison of the proportion of people adherent
to medication stratiﬁed by study design; interven-
tional studies, all observational studies, and only
observational studies which adjust for confounders of
adherence.
6. A comparison of persistence duration in all studies
(stratiﬁed by the deﬁnition used for persistence; all
deﬁnitions providing a measure of duration, non-
persistence gap between reﬁlls ≥90 days, non-
persistence gap between reﬁlls ≥60 days).
7. A comparison of persistence duration stratiﬁed by
study design; interventional studies, all observational
Figure 1 A schematic representation of the possible pairwise comparisons of adherence and persistence between different
medication classes. Comparison with metformin is the primary outcome (black lines), but the additional pairwise comparisons
possible are secondary outcomes of interest (grey lines).
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studies, and only observational studies which adjust
for confounders of persistence.
For all meta-analyses, we will report tests for hetero-
geneity (Q statistics and I2).
Review registration
This review has been registered with PROSPERO (regis-
tration: CRD42015027865).
Updates to study protocol
If any updates to the study protocol are required, these
will be listed and included as supplementary informa-
tion alongside a ﬁnal manuscript, and updated on the
PROSPERO register.
Review time frames
We will aim to complete the review within a period of
1 year from the start of the literature search. This time
period excludes time spent following submission of a
ﬁnal manuscript and article peer review.
CONCLUSIONS
This review and, if possible, meta-analysis, will provide
important information on patient adherence and persist-
ence with the different classes of diabetes therapies. This
is one of the key components of medication effective-
ness, and will help to guide clinical decision-making
about which is the optimum second-line or third-line
diabetes therapy to initiate. The review will also enable
key recommendation for further research in this area to
be made.
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